Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XZP-5809-TT1 in T790M-positive NSCLC (Phase I/II)
CTR20202033Phase 2Terminated
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of xzp-5809 in non-small cell lung cancer (NSCLC), sponsored by Xuanzhu Biopharmaceutical. Started Oct 2020; status: terminated.
02
Drugs
xzp-5809
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202033.